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There are many families in which several individuals have a history of early heart attack. This implies that in such families a major genetic component contributes to the risk of developing ischae-mic heart disease. Molecular biology techniques may allow the identification of individuals who are at high risk of developing ischaemic heart disease because they have this inherited component. Such individuals could be monitored closely and advised on diet and life style or possibly offered drug treatment to reduce their subsequent risk of early heart attack.
When will cardiologists be able to ask for a certain gene probe test to be carried out on a patient before they decide on what advice to give the patient and his family on prognosis, or the treatment to be offered, or even the diagnosis? At the current rate of progress useful tests may become available within the next few years. At present the best example of how these tests can be usefully applied to patients with atherosclerosis is in the presymptomatic diagnosis of familial hypercholesterolaemia. Analysis of DNA samples from the grandparents will resolve this problem (fig 2b) . The affected grandfather has the genotype V2V2, and the normal grandmother has VI VI. This means the familial hypercholesterolaemia gene must have been inherited with the V2 allele from the grandfather. It is likely that the grandfather will already be dead of an early heart attack. In this situation we can still carry out the diagnosis based on a sample from the grandmother, because platelet aggregation. In addition, there may be inherited defects in some of the structural components of the heart or blood vessel walls that may predispose to cardiovascular disease in later life. For instance, subtle defects in a cardiac specific collagen in the heart valves may be causing some forms of mitral valve prolapse17 and this too would be amenable to these methods of analysis.
It therefore seems likely that molecular biology will become a useful tool for the cardiologist. The challenge for the next few years is to identify the genes and the mutations of these genes that are involved in determining an individual's risk for developing coronary artery disease. For the patient presenting with myocardial infarction, conventional management methods may remain paramount. The new techniques, however, may allow a better understanding of the particular genetic factors responsible for the patient's existing coronary artery disease. This knowledge will improve the prognosis of the patient, who can be treated more appropriately, and will allow early diagnosis of other family members who also have a genetic predisposition to atherosclerosis. It is hoped that this information will make a useful contribution to an overall strategy to reduce an individual's risk of coronary artery disease.
